Chittorgarh.com Logo
Loading...

Advanced Enzyme IPO Details

Issue Open Jul 20, 2016
Issue Close Jul 22, 2016
IPO Price ₹896
Face Value ₹10
IPO Size ₹411.49 Cr
Listing At BSE, NSE
IPO Lot Size 16
  1. Happiest Minds IPO 8th most subscribed public issue of the last decade

    Mon, 06 Sep 2021 17:00:00 GMT

    The IPO of the Mumbai-headquartered digital IT ... Systems (September 2011), Dixon Technologies (September 2017), Advanced Enzyme Technologies (July 2016), IRCTC (October 2019) and Avenue ...

  2. All You Need To Know Going Into Trade On August 20

    Fri, 20 Aug 2021 00:24:00 GMT

    Advanced Enzyme Technologies: Completed the acquisition of additional ... The selling shareholders may also undertake a pre-IPO placement worth Rs 200 crore before filing the red herring prospectus, ...

  3. Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

    Wed, 08 Sep 2021 01:57:00 GMT

    It’s not just hot spaces that Paul Hudson wants Sanofi to lead in. The CEO’s latest, $1.9 billion M&A gamble points straight to Kadmon $KDMN and its newly approved drug, Rezurock, which is billed as a ...

  4. Rosana Kapeller rais­es $77M in bid to make re­peatome drugs a re­al­i­ty

    Tue, 14 Sep 2021 03:43:00 GMT

    Given the choice, Rosana Kapeller would have picked different circumstances to be a first time founder-CEO. The longtime computational biologist, an early veteran of Millennium and Nimbus, began ...

  5. Fabindia considers raising up to USD 1 billion via IPO

    Fri, 10 Sep 2021 14:21:00 GMT

    However, it declined to confirm the development. The company is believed to be in talks with several investment banks, including SBI Capital Markets, ICICI Securities and JPMorgan, to manage its IPO, ...

  6. Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

    Tue, 24 Aug 2021 12:30:00 GMT

    What I mean by that is that Lantern's 2 most advanced assets - LP-100 ... population of GBM patients who over-express the DNA repair enzyme MGMT and are unresponsive to Temozolomide that may ...

  7. The Daily Biotech Pulse: Early Approval For Ascendis Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO

    Thu, 26 Aug 2021 05:48:00 GMT

    Codexis Receives Purchase Orders For High-Performance Enzyme Valued At $15M Codexis ... of adult patients with previously treated, locally advanced or metastatic CCA with an IDH1 mutation as ...

  8. Lipocines LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

    Thu, 26 Aug 2021 15:14:00 GMT

    Subjects with advanced fibrosis (F2-F3) and steatohepatitis (inflammation on liver biopsy) were also eligible. Subjects were randomized 1:1:1 to one of three arms (Treatment A, a twice daily oral ...

  9. Sansera Engineering IPO, Zee Entertainment to Pharma Stocks - here are top Buzzing Stocks today

    Tue, 14 Sep 2021 02:49:00 GMT

    Sansera Engineering IPO: The initial public offering (IPO) of the auto component manufacturer Sansera Engineering that opened for subscription today was subscribed 0.22 times by 12:23 pm. The public ...

  10. Exclusive-Russian car-sharing firm Delimobil eyes $350 million New York IPO in autumn -sources

    Tue, 07 Sep 2021 03:52:00 GMT

    In June, Delimobil said VTB's minority stake was worth $75 million. Delimobil, which operates a total fleet of more than 16,000 vehicles in Russia, first announced IPO plans in 2019, saying it would ...

  11. Explained: How share allotment process works for IPO oversubscription, undersubscription

    Sat, 21 Aug 2021 22:51:00 GMT

    IPOs are raining these days. Thanks! To the bull market which has increased the confidence of investors to apply for the IPOs and be a part of a company in its initial listing days. While writing ...

  12. Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

    Thu, 19 Aug 2021 13:04:00 GMT

    Completed Enrollment of Phase 2 Myelofibrosis Trial: In May 2021, Imago completed enrollment of 89 patients with advanced myelofibrosis in its Phase ... Successful Completion of Initial Public ...

Advanced Enzyme IPO Alerts

1. Advanced Enzyme Technologies Ltd IPO - Listing  Friday, July 29, 2016 7:05:19 AM

Advanced Enzyme IPO Listing Date & Information:

› Listing Date: Monday, August 1, 2016
› BSE Script Code: 540025
› NSE Symbol: ADVENZYMES
› Listing In: B Group of Securities
› ISIN: INE837H01012
› Issue Price: Rs. 896.00 Per Equity Share
› Face Value: Rs. 10.00 Per Equity Share

2. Advanced Enzyme Technologies Ltd IPO - Allotment  Thursday, July 28, 2016 7:03:45 AM

Advanced Enzyme Technologies Ltd IPO Allotment Status is now available online.

Advanced Enzyme Technologies Ltd is an India based company engaged in research, development, manufacturing and marketing of Healthcare, Nutrition and Bio-Processing products.

The Initial Public Offer of Advanced Enzyme subscribed 116.02 times (11.67 times in retail). Public Issue of Advanced Enzyme was closed for subscription on Jul 22, 2016.

3. Final Subscription Detail - Advanced Enzyme IPO  Friday, July 22, 2016 3:08:26 PM

Advanced Enzyme Technologies IPO Final Subscription Detail (BSE+NSE):

 

ADVANCED ENZYME TECHNOLOGIES LIMITED
Sr.No. Category No.of shares offered/reserved No. of shares bid for No. of times of total meant for the category
1 Qualified Institutional Buyers (QIBs) 918908 86406528 94.03
1(a) Foreign Institutional Investors(FIIs)      
1(b) Domestic Financial Institutions(Banks/ Financial Institutions(FIs)/ Insurance Companies)      
1(c) Mutual funds      
1(d) Others      
2 Non Institutional Investors 686989 270055920 393.10
2(a) Corporates      
2(b) Individuals(Other than RIIs)      
2(c) Others      
3 Retail Individual Investors(RIIs) 1602974 18699488 11.67
3(a) Cut Off      
3(b) Price bids      
4 Employees 25188 43584 1.73
3(a) Cut Off      
3(b) Price bids      
  Total 3234059 375205520 116.02
Updated as on 22 July 2016 at 2300 hrs

4. Advanced Enzyme Technologies Ltd IPO - Close  Friday, July 15, 2016 10:16:05 AM

Advanced Enzyme Technologies Ltd IPO to open on Jul 20, 2016 and close for subscription on Jul 22, 2016. Company is coming with IPO to sell 4,034,470 equity shares by the promoter of the company and raising Rs 50.00 Cr through a fresh issue. The equity shares of the company to be list at BSE and NSE.

5. Advanced Enzyme Technologies Ltd IPO - Open  Friday, July 15, 2016 10:15:48 AM

Advanced Enzyme Technologies Ltd is entering in the capital markets with an initial public offering (IPO) to carry out the sale of up to 4,034,470 equity shares by the selling shareholder. In addition, company is raise Rs 50.00 Cr through a fresh issue to invest in Advanced Enzymes USA, the wholly owned subsidiary for repayment / pre-payment of certain loans availed by Advanced Enzymes USA. The price band for the issue has been fixed at Rs 880 at lower level and Rs 896 at upper level.

Incorporated in 1989, Advanced Enzyme Technologies Ltd is an India based company engaged in research, development, manufacturing and marketing of Healthcare, Nutrition and Bio-Processing products.

The issue opens on Jul 20, 2016 and closes for subscription on Jul 22, 2016. The equity shares of the issue are proposed to be list on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Advanced Enzyme IPO News & Events FAQs

The Advanced Enzyme IPO is proposed to open on Jul 20, 2016. The IPO application ends on Jul 22, 2016.

Retail investors can apply in the retail or non-institutional investor category from Jul 20, 2016 to Jul 22, 2016. The Advanced Enzyme IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).

The Advanced Enzyme IPO will open for subscription on Jul 20, 2016. The public issue will close on Jul 22, 2016.